首页>
外国专利>
use of rifaximin and rifaximin containing pharmaceutical compositions for the treatment of helicobacter pylori related magendyspepsie
use of rifaximin and rifaximin containing pharmaceutical compositions for the treatment of helicobacter pylori related magendyspepsie
展开▼
机译:利福昔明和含有利福昔明的药物组合物在治疗幽门螺杆菌相关的乳源性消化不良中的用途
展开▼
页面导航
摘要
著录项
相似文献
摘要
This invention refers to the use of the rifamycin antibiotic known by the name of rifaximin (INN) and to pharmaceutical compositions containing it in the oral treatment of the forms of gastric dyspepsia caused by bacteria known as Helicobacter pylori. Rifaximin may be administered in any oral pharmaceutical form, particularly tablets, capsules, sugar coated tablets, granules and syrups containing from 200 to 2000 mg of active principle, at a daily dosage of between 400 and 2000 mg.
展开▼